Skip to main content

Table 2 Risk of clinical outcomes in ICU patients with and without COVID-19

From: Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study

Clinical outcomes ICU COVID-19
Negative
(N = 93)
ICU COVID-19
Positive
(N = 78)
Unadjusted relative risk (95% CI) p value Model 1 relative risk (95% CI) p value Model 2 relative risk (95% CI) p value
In-hospital mortality 20 (22) 20 (26) 1.19 (0.69, 2.05) 0.53 1.24 (0.74, 2.10) 0.41 1.50 (0.93, 2.41) 0.10
ARDS 23 (25) 28 (36) 1.45 (0.91, 2.30) 0.11 1.39 (0.87, 2.22) 0.17 1.32 (0.87, 1.98) 0.19
Shock requiring vasopressor therapy 43 (46) 39 (50) 1.08 (0.79, 1.48) 0.62 1.07 (0.79, 1.45) 0.67 1.14 (0.84, 1.54) 0.40
AKIa 24 (26) 23 (29) 1.06 (0.66, 1.71) 0.81 0.96 (0.60, 1.54) 0.86 1.04 (0.64, 1.69) 0.87
Severe AKIa 11 (12) 12 (15) 1.21 (0.57, 2.57) 0.63 1.08 (0.50, 2.31) 0.85 1.13 (0.51, 2.52) 0.77
New dialysisa 6 (6) 8 (10) 1.48 (0.54, 4.06) 0.45 1.31 (0.48, 3.58) 0.60 1.60 (0.63, 4.09) 0.33
Thromboembolism 14 (15) 11 (14) 0.94 (0.45, 1.94) 0.86 0.83 (0.40, 1.71) 0.62 0.60 (0.28, 1.27) 0.18
  1. ARDS acute respiratory distress syndrome, APACHE III acute physiology and chronic health evaluation, AKI acute kidney injury. Model 1 adjusted: age, gender, body mass index and APACHE III. Model 2 includes model 1 variables and Charlson comorbidity index. Relative risk regression with 95% confidence intervals. Relative risk (RR) estimates are comparing COVID-19 to non-COVID-19 patients 
  2. aAll AKI outcomes excluded patients on hemodialysis prior to study enrollment, which included 3 patients in the COVID-19 group and 10 patients in the non-COVID-19 group